STEREOSELECTIVITY OF THE CARBONYL REDUCTION OF DOLASETRON IN RATS, DOGS, AND HUMANS

被引:27
作者
DOW, J
BERG, C
机构
[1] Department of Drug Metabolism, Marion Merrell Dow, Strasbourg
关键词
DOLASETRON; CHIRAL REDUCTION; FORMATION OF (+)-(R)-ENANTIOMER OF REDUCED DOLASETRON;
D O I
10.1002/chir.530070506
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The initial step in the metabolism of dolasetron or MDL 73,147EF [(2 alpha, 6 alpha, 8 alpha, 9a beta)-octahydro-3-oxo-2, 6-methano-2H-quinolizin-8-yl 1H-indol-3-carboxylate, monomethanesulfonate] is the reduction of the prochiral carbonyl group to give a chiral secondary alcohol ''reduced dolasetron.'' An HPLC method, using a chiral column to separate reduced dolasetron enantiomers, has been developed and used to measure enantiomers in urine of rats, dogs, and humans after dolasetron administration, In all cases, the reduction was enantioselective for the (+)-(R)-enantiomer, although the dog showed lower stereoselectivity, especially after iv administration. An approximate enantiomeric ratio (+/-) of 90:10 was found in rat and human urine, The contribution of further metabolism to this enantiomeric ratio was considered small as preliminary studies showed that oxidation of the enantiomeric alcohols by human liver microsomes demonstrated only minor stereoselectivity, Further evidence for the role of stereoselective reduction in man was obtained from in vitro studies, where dolasetron was incubated with human whole blood. The enantiomeric composition of reduced dolasetron formed in human whole blood was the same as that found in human urine after administration of dolasetron. Enanitioselectivity was not due to differences in the absorption, distribution, metabolism, or excretion of enantiomers, as iv or oral administration of rac-reduced dolasetron to rats and dogs lead to the recovery, in urine, of essentially the same enantiomeric composition as the dose administered, It is fortuitous that the (+)-(R)enantiomer is predominantly formed by carbonyl reductase, as it is the more active compound. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:342 / 348
页数:7
相关论文
共 14 条
  • [1] 5-HT3 RECEPTOR ANTAGONISTS - AN OVERVIEW OF THEIR PRESENT STATUS AND FUTURE POTENTIAL IN CANCER THERAPY-INDUCED EMESIS
    AAPRO, MS
    [J]. DRUGS, 1991, 42 (04) : 551 - 568
  • [2] PHARMACOLOGY OF THE HUMAN METABOLITES OF DOLASETRON, AN ANTIEMETIC 5-HT3 RECEPTOR ANTAGONIST
    BIGAUD, M
    ELANDS, J
    KASTNER, PR
    BOHNKE, RA
    EMMERT, LW
    GALVAN, M
    [J]. DRUG DEVELOPMENT RESEARCH, 1995, 34 (03) : 289 - 296
  • [3] HUMAN DOLASETRON PHARMACOKINETICS .1. DISPOSITION FOLLOWING SINGLE-DOSE INTRAVENOUS ADMINISTRATION TO NORMAL-MALE SUBJECTS
    BOXENBAUM, H
    GILLESPIE, T
    HECK, K
    HAHNE, W
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1992, 13 (09) : 693 - 701
  • [4] HUMAN DOLASETRON PHARMACOKINETICS .2. ABSORPTION AND DISPOSITION FOLLOWING SINGLE-DOSE ORAL-ADMINISTRATION TO NORMAL-MALE SUBJECTS
    BOXENBAUM, H
    GILLESPIE, T
    HECK, K
    HAHNE, W
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1993, 14 (02) : 131 - 141
  • [5] ALPHA-METHOXY-ALPHA-TRIFLUOROMETHYLPHENYLACETIC ACID, A VERSATILE REAGENT FOR DETERMINATION OF ENANTIOMERIC COMPOSITION OF ALCOHOLS AND AMINES
    DALE, JA
    DULL, DL
    MOSHER, HS
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1969, 34 (09) : 2543 - &
  • [6] DULERY BD, COMMUNICATION
  • [7] STEREOSPECIFIC REDUCTION OF HALOPERIDOL IN HUMAN TISSUES
    EYLES, DW
    POND, SM
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 44 (05) : 867 - 871
  • [8] MAMMALIAN CARBONYL REDUCTASES
    FELSTED, RL
    BACHUR, NR
    [J]. DRUG METABOLISM REVIEWS, 1980, 11 (01) : 1 - 60
  • [9] GITTOS MW, 1989, ACTUAL CHIM THER, V16, P187
  • [10] PHARMACOLOGICAL PROPERTIES OF DOLASETRON, A POTENT AND SELECTIVE ANTAGONIST AT 5-HT3 RECEPTORS
    MILLER, RC
    GALVAN, M
    GITTOS, MW
    VANGIERSBERGEN, PLM
    MOSER, PC
    FOZARD, JR
    [J]. DRUG DEVELOPMENT RESEARCH, 1993, 28 (01) : 87 - 93